 eYugoslavia.com | Biogen Idec, Abbott Say SELECT Phase 2B Trial For RRMS Compound Met Primary Goal RTT News (RTTNews) - Biotechnology firms Biogen Idec Inc. (BIIB: News ) and Abbott Laboratories (ABT: News ) announced Saturday that the investigational compound daclizumab high-yield process or DAC HYP met primary end point in the SELECT Phase 2b trial in ... Biogen Idec and Abbott Present Positive Data for Daclizumab HYP from Select ... Abbott, Biogen Idec announce additional results from daclizumab HYP Phase 2b ... Biogen Idec and Abbott Present Positive Data for Daclizumab HYP from Select ... |
